Artelo Biosciences, Inc.
ARTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.02 | -0.00 |
| FCF Yield | -96.84% | -6.75% | -9.27% | -74.76% |
| EV / EBITDA | -0.95 | -2.04 | -6.97 | -0.31 |
| Quality | ||||
| ROIC | -962.31% | 596.59% | -318.47% | -128.74% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.12 | 0.13 | 0.67 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -580.54% | 67.81% | 37.79% | -30.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.25 | 0.38 | 0.27 | 0.59 |
| Interest Coverage | -27.83 | -43.75 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |